Bioneer Corporation (064550.KQ)
KRW 19520.0
(-3.84%)
KRW 19520.0
(-3.84%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 791.75 Million KRW | -149.39% |
| 2022 | 10.74 Billion KRW | -76.15% |
| 2021 | 45.05 Billion KRW | -56.96% |
| 2020 | 104.66 Billion KRW | 1126.66% |
| 2019 | -10.19 Billion KRW | 12.37% |
| 2018 | -11.63 Billion KRW | -88.64% |
| 2017 | -6.16 Billion KRW | 49.32% |
| 2016 | -12.17 Billion KRW | -218.95% |
| 2015 | -3.81 Billion KRW | 55.84% |
| 2014 | -8.64 Billion KRW | -136.95% |
| 2013 | -3.64 Billion KRW | 16.12% |
| 2012 | -4.34 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -595 Million KRW | -121.43% |
| 2024 Q3 | -7.65 Billion KRW | -1273.36% |
| 2024 Q1 | 2.77 Billion KRW | 129.76% |
| 2023 Q4 | -9.33 Billion KRW | -517.78% |
| 2023 Q1 | -707.2 Million KRW | 81.71% |
| 2023 Q3 | 2.23 Billion KRW | -10.61% |
| 2023 FY | -5.3 Billion KRW | -149.39% |
| 2023 Q2 | 2.49 Billion KRW | 453.29% |
| 2022 Q3 | 3.19 Billion KRW | 581.7% |
| 2022 Q2 | -662.5 Million KRW | -106.75% |
| 2022 FY | 10.74 Billion KRW | -76.15% |
| 2022 Q1 | 9.81 Billion KRW | 76.35% |
| 2022 Q4 | -3.86 Billion KRW | -221.17% |
| 2021 Q3 | -794.59 Million KRW | -103.61% |
| 2021 Q2 | 22.03 Billion KRW | 24.31% |
| 2021 Q4 | 5.56 Billion KRW | 800.7% |
| 2021 FY | 45.05 Billion KRW | -56.96% |
| 2021 Q1 | 17.72 Billion KRW | -43.3% |
| 2020 Q2 | 32.03 Billion KRW | 7434.22% |
| 2020 Q3 | 42.35 Billion KRW | 32.23% |
| 2020 Q4 | 31.26 Billion KRW | -26.19% |
| 2020 Q1 | -436.79 Million KRW | 87.29% |
| 2020 FY | 104.66 Billion KRW | 1126.66% |
| 2019 Q1 | -2.8 Billion KRW | 18.28% |
| 2019 FY | -10.19 Billion KRW | 12.37% |
| 2019 Q4 | -3.43 Billion KRW | -116.41% |
| 2019 Q2 | -687.1 Million KRW | 75.55% |
| 2019 Q3 | -1.58 Billion KRW | -131.09% |
| 2018 Q4 | -3.43 Billion KRW | -50.93% |
| 2018 Q2 | -2.67 Billion KRW | 17.57% |
| 2018 Q1 | -3.24 Billion KRW | -34.51% |
| 2018 FY | -11.63 Billion KRW | -88.64% |
| 2018 Q3 | -2.27 Billion KRW | 14.82% |
| 2017 Q1 | -644.28 Million KRW | 78.61% |
| 2017 FY | -6.16 Billion KRW | 49.32% |
| 2017 Q4 | -2.41 Billion KRW | -60.44% |
| 2017 Q2 | -1.59 Billion KRW | -147.93% |
| 2017 Q3 | -1.5 Billion KRW | 5.9% |
| 2016 FY | -12.17 Billion KRW | -218.95% |
| 2016 Q1 | -2.36 Billion KRW | -145.43% |
| 2016 Q2 | -3.11 Billion KRW | -31.61% |
| 2016 Q4 | -3.01 Billion KRW | 33.97% |
| 2016 Q3 | -4.56 Billion KRW | -46.31% |
| 2015 Q4 | -965.31 Million KRW | -3105.84% |
| 2015 Q2 | -654.61 Million KRW | 67.31% |
| 2015 Q1 | -2 Billion KRW | 5.46% |
| 2015 FY | -3.81 Billion KRW | 55.84% |
| 2015 Q3 | -30.11 Million KRW | 95.4% |
| 2014 Q3 | -2.4 Billion KRW | 5.82% |
| 2014 Q1 | -1.56 Billion KRW | 10.0% |
| 2014 FY | -8.64 Billion KRW | -136.95% |
| 2014 Q4 | -2.11 Billion KRW | 11.97% |
| 2014 Q2 | -2.55 Billion KRW | -63.54% |
| 2013 Q2 | -759.97 Million KRW | -417.58% |
| 2013 Q4 | -1.73 Billion KRW | -72.82% |
| 2013 Q3 | -1 Billion KRW | -32.14% |
| 2013 Q1 | -146.83 Million KRW | -347.83% |
| 2013 FY | -3.64 Billion KRW | 16.12% |
| 2012 FY | -4.34 Billion KRW | 0.0% |
| 2012 Q4 | 59.24 Million KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 100.633% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | 124.102% |
| BINEX Co., Ltd. | 1.04 Billion KRW | 24.035% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | 115.605% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | 103.151% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | 102.561% |
| Helixmith Co., Ltd | -35.24 Billion KRW | 102.246% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | 108.4% |
| Medy-Tox Inc. | 17.32 Billion KRW | 95.429% |
| Peptron, Inc. | -15.6 Billion KRW | 105.074% |
| Amicogen, Inc. | 2.05 Billion KRW | 61.493% |
| Genexine, Inc. | -41.24 Billion KRW | 101.92% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | 109.1% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 100.98% |
| ALTEOGEN Inc. | -9.73 Billion KRW | 108.132% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 99.215% |
| SillaJen, Inc. | -21.34 Billion KRW | 103.709% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | 69.937% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | 104.354% |
| Genomictree Inc. | -17.3 Billion KRW | 104.576% |
| MedPacto, Inc. | -28.75 Billion KRW | 102.754% |
| D&D Pharmatech | -13.48 Billion KRW | 105.871% |
| EASY BIO,Inc. | 20.63 Billion KRW | 96.162% |
| GI Innovation, Inc. | -55.6 Billion KRW | 101.424% |